ClinicalTrials.gg
Active, not recruitingNCT05217628Updated Jan 23, 2026

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

A Phase 2/3 interventional study of Basimglurant and Placebo in Trigeminal Neuralgia, sponsored by Noema Pharma AG. Active, not recruiting at 34 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Noema Pharma AG · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Trigeminal Neuralgia with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Trigeminal Neuralgia · United States.

Enrollment
Largest of 26
166 · median 29
Started
2022
with 4 others
Phase 2/3
3 of 34
none open now
Primary completion
2027-02
later than 4 of 10 live
Registered
27th of 34
by date
Lead sponsor
2 of 34
Noema Pharma AG

Among the 34 studies in Trigeminal Neuralgia with a site in United States, this one has the largest enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2022, is one of 3 in phase 2/3, reaches primary completion later than 4 of the 10 other live ones, and was the 27th registered.

Trigeminal Neuralgia

140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.

Browse Trigeminal Neuralgia studies →

Open to participants now

7 of the 34 studies in Trigeminal Neuralgia with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Trigeminal Neuralgia studies recruiting now, 18 (67%) set no upper age limit and 3 (11%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Trigeminal Neuralgia with a site in United States, or all of them as a file.
02

Study summary

Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice.

This study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.

Read the detailed description

This study is designed to evaluate the efficacy and safety of basimglurant (NOE-101) in patients with TN. Basimglurant is a potent inhibitor of metabotropic glutamate receptor 5 (mGluR5) which controls a wide range of processes in both central and peripheral nervous system. Inhibition of the mGluR5 receptor has shown therapeutic potential for pain associated with conditions such as TN. The drug has been shown to have a favorable safety profile in adults, children and adolescents. The aim of the study is to determine whether Basimglurant decreases both duration and intensity of facial pain associated with TN by use of a patient pain diary and the Patient-reported Global Impression of Change (PGI-C) compared to baseline.

03

Conditions studied

  • Trigeminal Neuralgia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability and willingness to provide written and to comply with the study procedures.
  2. Fluency in the language of the investigator, study staff and the informed consent.
  3. Age 18-75 years.
  4. Diagnosis of primary trigeminal neuralgia (TN) as per the ICHD-3 criteria confirmed by the study neurologist.
  5. Experience pain due to TN and at baseline, experience at least 3 paroxysms per day of at least intensity of 4 or more on a pain intensity numerical rating scale (PI-NRS) during the last 7 days.
  6. Female patients who are either sterile or menopausal. For female patients with , must be neither pregnant nor lactating (with appropriate precautions and prior negative pregnancy tests).

Exclusion criteria

Exclusion Criteria (Summary):

Patients who meet any of the following criteria will be excluded from participation in this study:

  1. Current or prior history of any major psychiatric diagnoses unrelated to TN. Patients with TN-related depressive symptoms are permitted.
  2. Current or prior history of mania, or psychotic episodes.
  3. History of -defined substance dependence and/or substance abuse in the last six months [180 days], except for nicotine.
  4. Patient not willing to discontinue their current TN analgesic medication.
  5. Use of opioids, except for pain control on a prn basis as long as it does not exceed 2 days per week.
  6. Known allergic reaction to the drug or one of its components.
  7. Patients with secondary TN as per the ICHD-3 criteria.

    Medication history:

  8. Previous treatment with basimglurant, except with the prior agreement of the medical monitor.
  9. Treatment with antipsychotics within six months (180 days) of screening.
  10. Any investigational drug within 90 days prior to initiation of study drug.

    Medical status:

  11. Evidence of , uncontrolled, unstable medical conditions or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Subjects with myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke or during the 6 months prior to screening.
  12. Subject has a history of gastric, or small intestinal surgery (including gastric bypass, gastric banding, gastric sleeve, gastric balloon, etc.) that may, in the opinion of the investigator, may cause malabsorption, or has a disease of the GI tract that causes malabsorption.
  13. > 39kg/m²
  14. Patients with moderate or severely impaired hepatic function, ie, Pugh-Child score C.
  15. Patients with severe renal impairment, ie, or lower than 30mL/min.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Arm A: Basimglurant/NOE-101

    * Period 1 (Run-in: Baseline1 to Week 8): Basimglurant once daily dosing starting dose 1.5mg * Period 2 (Double blind: Weeks 9 to 20): Participants will receive double-blind treatment with Basimglurant once daily. * Open-label Extension (OLE): On completion of Period 2, participants will be offered open label treatment with Basimglurant in an open label extension for up to 52 weeks.

    Drug: Basimglurant

  • Placebo comparator
    Arm B: Placebo

    \- Period 2 (Double blind: Week 9 to Week 20): Participant randomized to placebo will receive the corresponding number of matching placebo capsules.

    Other: Placebo

Interventions

  • Period 1: Basimglurant 1.5 to 3.5 mg QD titrated on individual tolerability. Period 2: Patients randomized to receive either double blind Basimglurant at the tolerated dose from Period 1 or Placebo. OLE: Open label Basimglurant at the dose tolerated from Period 2, patients previously assigned placebo in period to be titrated to the Period 1.

    Also known as: NOE-101

  • OtherPlacebo

    Participant randomized to receive matching placebo once daily.

06

What researchers measure

Primary outcomes

  1. Period 1: Incidence and severity of adverse events, laboratory, vital signs and cardiovascular events.

    Change in pain as measured by the pain diary (TnED).

    Time frame: 8 weeks

  2. Period 2: Time to Loss of Efficacy or pain recurrence defined as the confirmed increase in the number of weekly paroxysms or re-emergence of continuous pain and/or the need for rescue medication.

    To assess the maintenance of effect on pain.

    Time frame: 12 weeks

  3. Open Label Extension: Incidence and severity of adverse events, laboratory, vital signs and cardiovascular events.

    To evaluate the long-term safety of basimglurant daily dosing.

    Time frame: 52 weeks

Secondary outcomes

  1. Period 2: Mean change in the total patient-rated Penn-Facial Pain Scale-Revised (Penn-FPS-R) scale compared with Period 2 baseline (BL2).

    Impact on facial pain.

    Time frame: 12 weeks

  2. Period 2: Frequency of attacks (paroxysms).

    Impact on facial pain measured by patient rated scale via Penn-FPS-R

    Time frame: 12 weeks

  3. Period 2: Severity of attacks (paroxysms).

    Impact on facial pain measured by patient rated scale via Penn-FPS-R

    Time frame: 12 weeks

  4. Period 2: Severity of continuous pain.

    Impact on facial pain measured by patient rated scale via Penn-FPS-R

    Time frame: 12 weeks

  5. Period 2: Duration of continuous pain.

    Impact on facial pain measured by patient rated scale via Penn-FPS-R

    Time frame: 12 weeks

  6. Period 2: Change in Patient Global Impression of Change (P-GIC).

    Impact on facial pain.

    Time frame: 12 weeks

  7. Period 2: Change in Medication Satisfaction Questionnaire (MSQ).

    Impact on facial pain.

    Time frame: 12 weeks

  8. Open Label Extension: Frequency of attacks (paroxysms).

    Evaluate the continued efficacy of basimglurant on facial pain measured by patient rated scale via Penn-FPS-R

    Time frame: 52 weeks

  9. Open Label Extension: Severity of attacks (paroxysms).

    Evaluate the continued efficacy of basimglurant on facial pain measured by patient rated scale via Penn-FPS-R

    Time frame: 52 weeks

  10. Open Label Extension: Severity and duration of continuous pain reported in patient pain diary.

    Evaluate the continued efficacy of basimglurant on facial pain.

    Time frame: 52 weeks

  11. Open Label Extension: Measure Global Impression of Severity as captured by PGI-S.

    Evaluate the continued efficacy of basimglurant on facial pain.

    Time frame: 52 weeks

Other outcomes

  1. Period 1: Mean change from Period 1 baseline (BL1) to Week 8 in the total patient-rated Penn-Facial Pain Scale-Revised (Penn-FPS-R) scale.

    Evaluate 8-week once daily basimglurant on pain associated with TN on the following: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction

    Time frame: 8 weeks

  2. Period 1: Measure Global Impression of change from Period 1 baseline (BL1) to Week 8.

    Evaluate 8-week once daily basimglurant on pain associated with TN on the following: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction

    Time frame: 8 weeks

  3. Period 1: Number and severity of attacks (paroxysms).

    Evaluate 8-week once daily basimglurant on pain associated with TN on the following: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction

    Time frame: 8 weeks

  4. Period 1: Duration of continuous pain compared with BL1.

    Evaluate 8-week once daily basimglurant on pain associated with TN on the following as measured by patient rated scale via Penn-FPS-R: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction

    Time frame: 8 weeks

  5. Period 1: Severity of continuous pain compared with BL1.

    Evaluate 8-week once daily basimglurant on pain associated with TN on the following as measured by patient rated scale via Penn-FPS-R: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction

    Time frame: 8 weeks

  6. Period 1: Number of pain free days.

    Evaluate 8-week once daily basimglurant on pain associated with TN on the following: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction

    Time frame: 8 weeks

  7. Period 1: Patient reported rating of the Medication Satisfaction Questionnaire (MSQ).

    Evaluate 8-week once daily basimglurant on pain associated with TN on the following: * Impact on Facial Pain * Patient perceived change of the pain * Pain assessments * Pain freedom * Patient medication satisfaction

    Time frame: 8 weeks

  8. Period 2: The impact of pain on general activities of daily living captured in patient diary cards.

    Time frame: 12 weeks

07

Study locations

34 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Feb 1, 2022
StartActual
Jan 11, 2022
Primary completionEst.
Feb 2, 2027
CompletionEst.
Apr 24, 2027
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05217628
Lead sponsor
Noema Pharma AG
Responsible party
Sponsor
First posted
Feb 1, 2022
Start date
Jan 11, 2022
Primary completion
Feb 2, 2027 (estimated)
Completion
Apr 24, 2027 (estimated)
Last update
Jan 23, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Basimglurant

Start the discussion